The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Subscribe To Our Newsletter & Stay Updated
